Company · Public · GENF
Genflow Biosciences
London-listed gene therapy company developing AAV-delivered SIRT6 programmes aimed at age-related disease, built around the centenarian-associated SIRT6 variant.
Listing
Public
Ticker
GENF
Headquarters
London, UK
Founded
2020
Technology
SIRT6 gene therapy (AAV)
Category
Longevity thesis
SIRT6 variants enriched in centenarians are a human-genetics-validated starting point for gene therapy in age-related disease.
Programmes
- GF-1002Preclinical
Age-related disease (SIRT6)
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.